论文部分内容阅读
目的探讨马来酸依那普利片与硝苯地平缓释片两种不同药物治疗高血压的成本-效果。方法选取2013年3月至2014年1月我院高血压患者105例,将其按随机数字表法分为A组和B组。A组患者给予马来酸依那普利片治疗,B组患者则给予硝苯地平缓释片治疗。两组患者均接受6周治疗,治疗结束后,对比两组患者的治疗总有效率、不良反应率,并运用药物经济学基本原理分析两种药物的成本-效果比。结果 A组患者治疗总有效率为96.2%(50/52),B组为94.3%(50/53),两组患者总有效率比较,差异无统计学意义(P>0.05)。A组患者治疗不良反应发生率为7.7%(4/52),B组为9.4%(3/53),两组不良反应率比较,差异无统计学意义(P>0.05)。A组成本-效果比(C/E)为112.8,明显低于B组的303.5(P<0.05)。假设两种高血压药物治疗总成本降低10%,A组成本-效果比为101.5,明显低于B组的273.1(P<0.05)。结论在高血压治疗中,马来酸依那普利片和硝苯地平缓释片治疗效果、不良反应类似,但马来酸依那普利片更具有成本-效果优势。
Objective To investigate the cost-effectiveness of two different drugs, enalapril maleate and nifedipine sustained-release tablets. Methods From March 2013 to January 2014, 105 cases of hypertensive patients in our hospital were divided into groups A and B according to random number table. Patients in group A received enalapril maleate, while patients in group B received nifedipine sustained-release tablets. Both groups received six weeks of treatment. After treatment, the total effective rate and adverse reaction rate were compared between the two groups, and the cost-effectiveness ratio of the two drugs was analyzed using the principles of pharmacoeconomics. Results The total effective rate was 96.2% (50/52) in group A, 94.3% (50/53) in group B, and the total effective rate was no significant difference between the two groups (P> 0.05). The incidence of adverse reactions in group A was 7.7% (4/52) in group A and 9.4% (3/53) in group B, respectively. There was no significant difference in adverse reactions between the two groups (P> 0.05). The cost-effectiveness ratio (C / E) of group A was 112.8, which was significantly lower than that of group B (303.5, P <0.05). Assuming a 10% reduction in the total cost of the two antihypertensive drugs, the cost-benefit ratio for group A was 101.5, significantly lower than that of group B, 273.1 (P <0.05). Conclusions In the treatment of hypertension, enalapril maleate and nifedipine sustained-release tablets have similar efficacy and adverse reactions, but enalapril maleate is more cost-effective.